B. Eriksson
Cardiology and Cardiovascular Medicine · 2001–2010
A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Cardiology and Cardiovascular Medicine — 12 citations into it; #827 of 906 by trust here, #106 by citations
- Internal Medicine — 12 citations into it; #18 of 19 by trust here, #3 by citations
Whom B. Eriksson trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts B. Eriksson overall
Papers from B. Eriksson's perspective
Ordered by how strongly the researchers B. Eriksson trusts endorse each paper. Same corpus, a different order for every researcher.
- Health measurement scales
- The VISA-A questionnaire: a valid and reliable index of the clinical severity of Achilles tendinopathy (British Journal of Sports Medicine)
- Validation of the Foot and Ankle Outcome Score for Ankle Ligament Reconstruction (Foot & ankle international)
- Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (Chest)
- Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (New England Journal of Medicine)
- Generalized Linear Models
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. (New England Journal of Medicine)
- American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. (Journal of the American College of Cardiology)
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor (Journal of Thrombosis and Haemostasis)
- Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. (Archives of Internal Medicine)
Their papers
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients (2010) — 2,386 citations
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. (2008) — 1,133 citations
- Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (2008) — 1,470 citations
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial (2007) — 1,051 citations
- The Achilles Tendon Total Rupture Score (ATRS) (2007) — 853 citations
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. (2007) — 1,166 citations
- Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. (2002) — 754 citations
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. (2001) — 650 citations
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. (2001) — 634 citations